Innehållet på denna webbplats är endast avsett för veterinärer eller andra professionella inom djurhälsovård.
Genom att använda denna webbplats accepterar du ovanstående.
Intervacc has presented results from clinical trials at a scientific meeting on strangles
”Getting to grips with strangles” is a regularly recurring international scientific meeting on research on strangles a highly contagious horse disease. At the meeting held in Montanan, USA, in September 2017, Intervacc’s CEO, Jan-Ingmar Flock,...Intervacc has presented results from clinical trials at WEAS 2017
The WEAS (World Equine Airway Symposium) is a regularly recurring international scientific meeting on diseases of the horse’s airways. At WEAS 2017 in Copenhagen in July 2017, Intervacc CEO Jan-Ingmar Flock presented data from the clinical trials conducted with...Intervacc now on Introduce.se
Starting today March 1st, 2017 Intervacc becomes overviewed by Introduce.se Intervacc is now presented on introduce.se, a Swedish language website designed to provide overviews of publicly traded companies and to provide independent investor information. The...Strangvac® clinical trials confirm expected efficacy
A series of trials have been conducted at the Animal Health Trust, Newmarket, England. The trials were aimed to measure the safety, immunogenicity, efficacy and DIVA (differentiates infected from vaccinated animals) capability of the Strangvac® vaccine. The...Intervacc signs agreement for optimization of manufacturing
Intervacc is pleased to announce that an agreement has now been signed with PX´Therapeutics, Grenoble, France, for process optimization of Strangvac. PX´Therapeutics, a subsidiary of Aguettant pharmaceutical group, has the experience, facilities and personnel to...Nyhetstjänster
